Skip to main content

PBYI

Stock
Health Care
Biotechnology

Performance overview

PBYI Price
Price Chart

Forward-looking statistics

Beta
1.55
Risk
74.16%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

we focus on in-licensing innovative drug candidates that are undergoing or have already completed initial clinical testing for the treatment of various forms of cancer and then seek to further develop these drug candidates for commercial use.

Company info

SectorHealth Care
IndustryBiotechnology
Employees238
Market cap$170.0M

Fundamentals

Enterprise value$138.8M
Revenue$232.7M
Revenue per employee—
Profit margin16.36%
Debt to equity63.55

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$0.78
Dividend per share—
Revenue per share$4.75
Avg trading volume (30 day)$1M
Avg trading volume (10 day)$1M
Put-call ratio—

Macro factor sensitivity

Growth+10.2
Credit-0.1
Liquidity-5.2
Inflation+7.0
Commodities+3.3
Interest Rates-0.9

Valuation

Dividend yield0.00%
PEG Ratio14.92
Price to sales0.76
P/E Ratio14.92
Enterprise Value to Revenue0.60
Price to book1.83

Upcoming events

Next earnings dayMay 9, 2025
Next dividend day—
Ex. dividend day—

News

Why Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value Investors

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Puma Biotech (PBYI) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Investment Research (July 10, 2025)
Fast-paced Momentum Stock Puma Biotech (PBYI) Is Still Trading at a Bargain

Puma Biotech (PBYI) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Investment Research (June 24, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free